Assessment of ASPIRE and HOPE Adherence
Protocol Chair(s)
Baeten, Jared (Protocol Chair)
Mgodi, Nyaradzo (Protocol Co-Chair)
Palanee-Phillips, Thesla (Protocol Co-Chair)
HIV Open-label Prevention Extension (HOPE)
Primary Objective
MTN-029 is a Phase I study that seeks to determine whether a vaginal ring containing the antiretroviral (ARV) drug dapivirine is a safe method for protecting against HIV infection when used by lactating women by assessing whether and how dapivirine is expressed in breast milk.
Protocol Chair(s)
Cranston, Ross (Protocol Chair)
MTN-026 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of a rectal gel containing the antiretroviral (ARV) drug dapivirine. The study will enroll approximately 24 men and women at two U.S. sites and take approximately 9-12 months to conduct.
Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Protocol Chair(s)
Mensch, Barbara (Protocol Co-Chair)
Montgomery, Elizabeth (Protocol Co-Chair)
van der Straten, Ariane (Protocol Chair)
An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial